Human cytomegalovirus UL27 is not required for viral replication in human tissue implanted in SCID mice
- PMID: 16571131
- PMCID: PMC1448171
- DOI: 10.1186/1743-422X-3-18
Human cytomegalovirus UL27 is not required for viral replication in human tissue implanted in SCID mice
Abstract
Inhibition of the human cytomegalovirus UL97 kinase by maribavir is thought to be responsible for the antiviral activity of this compound. Some mutations that confer resistance to maribavir map to UL97, however additional mutations that also confer resistance to the drug were mapped to UL27. These open reading frames share a low level of homology, yet the function of pUL27 remains unknown. A recombinant virus with a deletion in the UL27 open reading frame was reported previously to exhibit a slight replication deficit, but a more important function in vivo was hypothesized given its homology to the UL97 kinase. The potential for an important function in vivo was investigated by determining if these knockout viruses could replicate in human tissue implanted in SCID mice. None of the AD169 derived viruses replicated well in the implanted thymus/liver tissue, and is consistent with previous observations, although all of the viruses replicated to some degree in retinal tissue implants. Replication of the parent viruses was observed at 7 days post inoculation, whereas no replication was detected with any of the recombinant viruses with deletions in UL27. By day 14, replication was detected in two of the three knockout viruses and in all of the viruses by day 42. These data are consistent with minimal defects observed in cell culture, but are not consistent with an important role for UL27 in vivo. We conclude that UL27 is not required for viral replication in vivo.
Similar articles
-
Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir.J Virol. 2004 Jul;78(13):7124-30. doi: 10.1128/JVI.78.13.7124-7130.2004. J Virol. 2004. PMID: 15194788 Free PMC article.
-
Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27.J Virol. 2003 Nov;77(21):11499-506. doi: 10.1128/jvi.77.21.11499-11506.2003. J Virol. 2003. PMID: 14557635 Free PMC article.
-
Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.Antimicrob Agents Chemother. 2009 Jan;53(1):81-5. doi: 10.1128/AAC.01177-08. Epub 2008 Nov 3. Antimicrob Agents Chemother. 2009. PMID: 18981262 Free PMC article.
-
Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance.Antiviral Res. 2019 Mar;163:91-105. doi: 10.1016/j.antiviral.2019.01.011. Epub 2019 Jan 25. Antiviral Res. 2019. PMID: 30690043 Review.
-
Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir.Rev Med Virol. 2009 Jul;19(4):215-29. doi: 10.1002/rmv.615. Rev Med Virol. 2009. PMID: 19434630 Free PMC article. Review.
Cited by
-
The Cytomegalovirus Protein Kinase pUL97:Host Interactions, Regulatory Mechanisms and Antiviral Drug Targeting.Microorganisms. 2020 Apr 4;8(4):515. doi: 10.3390/microorganisms8040515. Microorganisms. 2020. PMID: 32260430 Free PMC article. Review.
-
Human cytomegalovirus UL28 and UL29 open reading frames encode a spliced mRNA and stimulate accumulation of immediate-early RNAs.J Virol. 2009 Oct;83(19):10187-97. doi: 10.1128/JVI.00396-09. Epub 2009 Jul 22. J Virol. 2009. PMID: 19625400 Free PMC article.
-
Antisense transcription in the human cytomegalovirus transcriptome.J Virol. 2007 Oct;81(20):11267-81. doi: 10.1128/JVI.00007-07. Epub 2007 Aug 8. J Virol. 2007. PMID: 17686857 Free PMC article.
-
Humanized mouse models of human cytomegalovirus infection.Curr Opin Virol. 2015 Aug;13:86-92. doi: 10.1016/j.coviro.2015.06.006. Epub 2015 Jun 25. Curr Opin Virol. 2015. PMID: 26118890 Free PMC article. Review.
-
The Role of Caspase-12 in Retinal Bystander Cell Death and Innate Immune Responses against MCMV Retinitis.Int J Mol Sci. 2021 Jul 29;22(15):8135. doi: 10.3390/ijms22158135. Int J Mol Sci. 2021. PMID: 34360899 Free PMC article.
References
-
- Lalezari JP, Aberg JA, Wang LH, Wire MB, Miner R, Snowden W, Talarico CL, Shaw S, Jacobson MA, Drew WL. Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob Agents Chemother. 2002;46:2969–2976. doi: 10.1128/AAC.46.9.2969-2976.2002. - DOI - PMC - PubMed
-
- McSharry JJ, McDonough A, Olson B, Talarico C, Davis M, Biron KK. Inhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94. Clin Diagn Lab Immunol. 2001;8:1279–1281. doi: 10.1128/CDLI.8.6.1279-1281.2001. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources